Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Beyer

Showing results (91-100 of 225) with videos related to

Pageof 23
Sort By:
Journal of Thrombosis and Thrombolysis|January 19, 2016
Guidance for the management of venous thrombosis in unusual sitesWalter Ageno, Jan Beyer-Westendorf, David A Garcia, et al.
Thrombosis Research|February 7, 2018
Effectiveness and safety of outpatient rivaroxaban versus warfarin for treatment of venous thromboembolism in patients with a known primary hypercoagulable stateCraig I Coleman, Alexander G G Turpie, Thomas J Bunz, et al.
The American Journal of Medicine|December 25, 2018
Impact of Prolonged Anticoagulation with Rivaroxaban on Provoked Venous Thromboembolism Recurrence: IMPROVE-VTECraig I Coleman, Alexander G G Turpie, Thomas J Bunz, et al.
Thrombosis Research|May 11, 2020
Anticoagulation with direct factor Xa inhibitors in transplant recipients: Results from the DRESDEN NOAC REGISTRY (NCT01588119)Jan Beyer-Westendorf, Sandra Marten, Christiane Naue, et al.
Thrombosis Journal|January 1, 2020
Evaluation of unmet clinical needs in prophylaxis and treatment of venous thromboembolism in at-risk patient groups: pregnancy, elderly and obese patientsBenjamin Brenner, Roopen Arya, Jan Beyer-Westendorf, et al.
Thrombosis Research|June 16, 2023
Clinical effectiveness and safety of edoxaban in obese patients - Results of the prospective Dresden NOAC Registry (NCT01588119)Luise Tittl, Christina Köhler, Sandra Marten, et al.
Thrombosis Research|May 27, 2022
Effectiveness and safety of edoxaban therapy in daily-care patients with atrial fibrillation. Results from the DRESDEN NOAC REGISTRYChristina Köhler, Luise Tittl, Sandra Marten, et al.
Thrombosis and Haemostasis|May 22, 2015
Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registryFranziska Michalski, Luise Tittl, Sebastian Werth, et al.
Thrombosis Journal|September 7, 2018
COSIMO - patients with active cancer changing to rivaroxaban for the treatment and prevention of recurrent venous thromboembolism: a non-interventional studyAlexander T Cohen, Anthony Maraveyas, Jan Beyer-Westendorf, et al.
Thrombosis Journal|April 24, 2019
Evaluation of unmet clinical needs in prophylaxis and treatment of venous thromboembolism in high-risk patient groups: cancer and critically illBenjamin Brenner, Russell Hull, Roopen Arya, et al.
Pageof 23

Showing results (91-100 of 225) with videos related to

Sort By:
Pageof 23
Journal of Thrombosis and Thrombolysis|January 19, 2016
Guidance for the management of venous thrombosis in unusual sitesWalter Ageno, Jan Beyer-Westendorf, David A Garcia, et al.
Thrombosis Research|February 7, 2018
Effectiveness and safety of outpatient rivaroxaban versus warfarin for treatment of venous thromboembolism in patients with a known primary hypercoagulable stateCraig I Coleman, Alexander G G Turpie, Thomas J Bunz, et al.
The American Journal of Medicine|December 25, 2018
Impact of Prolonged Anticoagulation with Rivaroxaban on Provoked Venous Thromboembolism Recurrence: IMPROVE-VTECraig I Coleman, Alexander G G Turpie, Thomas J Bunz, et al.
Thrombosis Research|May 11, 2020
Anticoagulation with direct factor Xa inhibitors in transplant recipients: Results from the DRESDEN NOAC REGISTRY (NCT01588119)Jan Beyer-Westendorf, Sandra Marten, Christiane Naue, et al.
Thrombosis Journal|January 1, 2020
Evaluation of unmet clinical needs in prophylaxis and treatment of venous thromboembolism in at-risk patient groups: pregnancy, elderly and obese patientsBenjamin Brenner, Roopen Arya, Jan Beyer-Westendorf, et al.
Thrombosis Research|June 16, 2023
Clinical effectiveness and safety of edoxaban in obese patients - Results of the prospective Dresden NOAC Registry (NCT01588119)Luise Tittl, Christina Köhler, Sandra Marten, et al.
Thrombosis Research|May 27, 2022
Effectiveness and safety of edoxaban therapy in daily-care patients with atrial fibrillation. Results from the DRESDEN NOAC REGISTRYChristina Köhler, Luise Tittl, Sandra Marten, et al.
Thrombosis and Haemostasis|May 22, 2015
Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registryFranziska Michalski, Luise Tittl, Sebastian Werth, et al.
Thrombosis Journal|September 7, 2018
COSIMO - patients with active cancer changing to rivaroxaban for the treatment and prevention of recurrent venous thromboembolism: a non-interventional studyAlexander T Cohen, Anthony Maraveyas, Jan Beyer-Westendorf, et al.
Thrombosis Journal|April 24, 2019
Evaluation of unmet clinical needs in prophylaxis and treatment of venous thromboembolism in high-risk patient groups: cancer and critically illBenjamin Brenner, Russell Hull, Roopen Arya, et al.
Pageof 23